StocktoriaBluejay Diagnostics, Inc. BJDX
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus
Chart by TradingView
2/9
Piotroski F — financial health
-16.09
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | — | — | — | $249,040 | — |
| Gross profit | — | — | — | $48,911 | — |
| Operating income | -$7.0M | -$7.2M | -$10.3M | -$9.3M | -$3.2M |
| Net income | -$6.8M | -$7.7M | -$10.0M | -$9.3M | -$3.5M |
| Operating cash flow | -$6.1M | -$7.8M | -$8.3M | -$7.7M | -$4.4M |
| Free cash flow | -$6.2M | -$8.1M | -$9.0M | -$8.9M | -$4.4M |
| Total assets | $7.1M | $6.7M | $4.9M | $13.5M | $21.0M |
| Total liabilities | $1.1M | $927,924 | $2.0M | $2.0M | $637,162 |
| Shareholders' equity | $6.0M | $5.7M | $2.9M | $11.5M | $20.4M |
| Ratios | |||||
| Gross margin | — | — | — | 19.6% | — |
| Operating margin | — | — | — | -3741.5% | — |
| Net margin | — | — | — | -3733.1% | — |
| FCF margin | — | — | — | -3590.1% | — |
| Return on assets | -96.2% | -115.9% | -204.5% | -68.8% | -16.6% |
| Return on equity | -114.6% | -134.7% | -343.8% | -80.6% | -17.1% |
| Current ratio | 4.88 | 6.05 | 1.82 | 7.19 | 32.43 |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -16.09 (distress)
- Working capital / assets 0.61
- Retained earnings / assets -5.832
- EBIT / assets -0.977
- Equity / liabilities 5.223
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001704287 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.